APT Medical 관리

관리 기준 확인 2/4

APT Medical CEO는 Zhenghui Cheng, Aug2016 에 임명되었습니다 의 임기는 8.25 년입니다. 는 CN¥ 9.61B 가치에 해당하는 회사 주식의 27.15% 직접 소유합니다. 9.61B. 경영진과 이사회의 평균 재임 기간은 각각 8.3 년과 5 년입니다.

주요 정보

Zhenghui Cheng

최고 경영자

CN¥3.3m

총 보상

CEO 급여 비율	n/a
CEO 임기	8.3yrs
CEO 소유권	27.2%
경영진 평균 재임 기간	8.3yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Shareholders Would Enjoy A Repeat Of APT Medical's (SHSE:688617) Recent Growth In Returns

Oct 16

Should You Be Adding APT Medical (SHSE:688617) To Your Watchlist Today?

Sep 19

More Unpleasant Surprises Could Be In Store For APT Medical Inc.'s (SHSE:688617) Shares After Tumbling 27%

Jul 25

APT Medical (SHSE:688617) Is Very Good At Capital Allocation

Jul 16

Are APT Medical Inc. (SHSE:688617) Investors Paying Above The Intrinsic Value?

Jun 20

APT Medical Inc. (SHSE:688617) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

May 10

APT Medical's (SHSE:688617) Promising Earnings May Rest On Soft Foundations

May 02

APT Medical (SHSE:688617) Knows How To Allocate Capital Effectively

Apr 10

Here's Why We Think APT Medical (SHSE:688617) Might Deserve Your Attention Today

Mar 19

CEO

Zhenghui Cheng (60 yo)

8.3yrs

테뉴어

CN¥3,310,100

보상

Mr. Zhenghui Cheng is Chairman of the Board and President of APT Medical Inc. and serves as General Manager since August 2016.

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhenghui Cheng	Chairman of the Board	8.3yrs	CN¥3.31m	27.15% CN¥ 9.6b
Zhenhua Dai	Deputy GM	5yrs	CN¥2.51m	1.8% CN¥ 636.2m
Yiqing Xu	Deputy GM & Director	18.1yrs	CN¥1.00m	2.59% CN¥ 915.7m
Yonggui Han	Deputy General Manager	no data	CN¥1.38m	0.19% CN¥ 65.8m
Fangyuan Liu	Deputy General Manager	10.3yrs	CN¥1.35m	0.027% CN¥ 9.6m
Wei Wang	Deputy General Manager	no data	CN¥1.38m	0.044% CN¥ 15.7m
Wang Jinhe	Deputy General Manager	1.6yrs	CN¥1.66m	데이터 없음

8.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 688617 의 관리팀은 노련하고 경험 (평균 재직 기간 8.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhenghui Cheng	Chairman of the Board	no data	CN¥3.31m	27.15% CN¥ 9.6b
Zhenhua Dai	Deputy GM	5yrs	CN¥2.51m	1.8% CN¥ 636.2m
Yiqing Xu	Deputy GM & Director	10.5yrs	CN¥1.00m	2.59% CN¥ 915.7m
Lijun Xia	Independent Director	5yrs	CN¥180.00k	데이터 없음
Guangrong Dai	Employee Representative Supervisor	5yrs	데이터 없음	0.00060% CN¥ 212.3k
Jing Xu	Director	2yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 이사회: 688617 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

APT Medical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

APT Medical Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.91 (vs CN¥1.50 in 3Q 2023)

Shareholders Would Enjoy A Repeat Of APT Medical's (SHSE:688617) Recent Growth In Returns

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

APT Medical Inc. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 27%

Price target increased by 9.6% to CN¥376

Should You Be Adding APT Medical (SHSE:688617) To Your Watchlist Today?

Second quarter 2024 earnings released: EPS: CN¥5.46 (vs CN¥1.60 in 2Q 2023)

More Unpleasant Surprises Could Be In Store For APT Medical Inc.'s (SHSE:688617) Shares After Tumbling 27%

Investor sentiment deteriorates as stock falls 29%

APT Medical (SHSE:688617) Is Very Good At Capital Allocation

APT Medical Inc. to Report First Half, 2024 Results on Aug 23, 2024

Are APT Medical Inc. (SHSE:688617) Investors Paying Above The Intrinsic Value?

APT Medical Inc., Annual General Meeting, Jun 27, 2024

APT Medical Inc. (SHSE:688617) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

APT Medical's (SHSE:688617) Promising Earnings May Rest On Soft Foundations

Price target increased by 10% to CN¥497

First quarter 2024 earnings released: EPS: CN¥2.10 (vs CN¥1.54 in 1Q 2023)

Shenzhen Mindray Technology Holdings Co., Ltd. completed the acquisition of 19.72% stake in APT Medical Inc. (SHSE:688617) from group of sellers.

APT Medical (SHSE:688617) Knows How To Allocate Capital Effectively

Consensus EPS estimates fall by 30%

APT Medical Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Here's Why We Think APT Medical (SHSE:688617) Might Deserve Your Attention Today

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 17%

Third quarter 2023 earnings released: EPS: CN¥2.18 (vs CN¥1.53 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥2.32 (vs CN¥1.38 in 2Q 2022)

New minor risk - Dividend sustainability

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings released: EPS: CN¥5.37 (vs CN¥3.19 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.71 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

APT Medical Inc. (SHSE:688617) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to CN¥281

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.63 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.63 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.43 in 1Q 2020)

APT Medical Inc. to Report Fiscal Year 2020 Results on Apr 27, 2021

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령